Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1995 1
1996 1
1997 1
1998 1
1999 1
2000 1
2001 4
2002 1
2003 1
2004 1
2005 4
2007 6
2008 7
2009 8
2010 6
2011 6
2012 15
2013 15
2014 14
2015 13
2016 14
2017 8
2018 16
2019 6
2020 8
2021 25
2022 14
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Results by year

Filters applied: . Clear all
Page 1
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC); Huson SM, Wolkenstein P, Evans DG. Plotkin SR, et al. Genet Med. 2022 Sep;24(9):1967-1977. doi: 10.1016/j.gim.2022.05.007. Epub 2022 Jun 9. Genet Med. 2022. PMID: 35674741 Free article.
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC); Huson SM, Evans DG, Plotkin SR. Legius E, et al. Among authors: plotkin sr. Genet Med. 2021 Aug;23(8):1506-1513. doi: 10.1038/s41436-021-01170-5. Epub 2021 May 19. Genet Med. 2021. PMID: 34012067 Free PMC article.
Neurofibromatoses.
Jordan JT, Plotkin SR. Jordan JT, et al. Among authors: plotkin sr. Hematol Oncol Clin North Am. 2022 Feb;36(1):253-267. doi: 10.1016/j.hoc.2021.08.010. Epub 2021 Oct 27. Hematol Oncol Clin North Am. 2022. PMID: 34756486 Review.
Neurofibromatoses.
Uhlmann EJ, Plotkin SR. Uhlmann EJ, et al. Among authors: plotkin sr. Adv Exp Med Biol. 2012;724:266-77. doi: 10.1007/978-1-4614-0653-2_20. Adv Exp Med Biol. 2012. PMID: 22411249 Review.
Neurofibromatosis and Schwannomatosis.
Plotkin SR, Wick A. Plotkin SR, et al. Semin Neurol. 2018 Feb;38(1):73-85. doi: 10.1055/s-0038-1627471. Epub 2018 Mar 16. Semin Neurol. 2018. PMID: 29548054 Review.
Benign Intracranial Tumors.
Jordan JT, Plotkin SR. Jordan JT, et al. Among authors: plotkin sr. Neurol Clin. 2018 Aug;36(3):501-516. doi: 10.1016/j.ncl.2018.04.007. Neurol Clin. 2018. PMID: 30072068 Review.
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JC, Ullrich NJ, Goldman S, Gutmann DH, Plotkin SR, Rosser T, Robertson KA, Widemann BC, Smith AE, Bessler WK, He Y, Park SJ, Mund JA, Jiang L, Bijangi-Vishehsaraei K, Robinson CT, Cutter GR, Korf BR; Neurofibromatosis Clinical Trials Consortium; Blakeley JO, Clapp DW. Fisher MJ, et al. Among authors: plotkin sr. Nat Med. 2021 Jan;27(1):165-173. doi: 10.1038/s41591-020-01193-6. Epub 2021 Jan 13. Nat Med. 2021. PMID: 33442015 Free PMC article. Clinical Trial.
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Lassman AB, Wen PY, van den Bent MJ, Plotkin SR, Walenkamp AME, Green AL, Li K, Walker CJ, Chang H, Tamir S, Henegar L, Shen Y, Alvarez MJ, Califano A, Landesman Y, Kauffman MG, Shacham S, Mau-Sørensen M. Lassman AB, et al. Among authors: plotkin sr. Clin Cancer Res. 2022 Feb 1;28(3):452-460. doi: 10.1158/1078-0432.CCR-21-2225. Epub 2021 Nov 2. Clin Cancer Res. 2022. PMID: 34728525 Free PMC article. Clinical Trial.
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB. Frigault MJ, et al. Among authors: plotkin sr. Blood. 2022 Apr 14;139(15):2306-2315. doi: 10.1182/blood.2021014738. Blood. 2022. PMID: 35167655 Free PMC article. Clinical Trial.
A practical guide to neuro-oncology fellowship.
Gonzalez Castro LN, Forst DA, Plotkin SR, Lee EQ. Gonzalez Castro LN, et al. Among authors: plotkin sr. J Neurooncol. 2022 Jan;156(1):73-79. doi: 10.1007/s11060-021-03897-2. Epub 2021 Dec 2. J Neurooncol. 2022. PMID: 34855097 Review.
186 results